HC Wainwright & Co. reiterated coverage on SpringWorks Therapeutics with a new price target

8/5/21 6:47:30 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SWTX alert in real time by email

HC Wainwright & Co. reiterated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $137.00 from $136.00 previously

Get the next $SWTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SWTX

Date	Price Target	Rating	Analyst
11/20/2024	$60.00	Outperform	Evercore ISI
2/5/2024	$75.00	Buy	Guggenheim
12/1/2022	$45.00	Buy	BofA Securities
9/8/2021	$97.00 → $105.00	Overweight	JP Morgan
8/5/2021	$136.00 → $137.00	Buy	HC Wainwright & Co.

More analyst ratings

HC Wainwright & Co. reiterated coverage on SpringWorks Therapeutics with a new price target

Chat with this insight

Recent Analyst Ratings for
$SWTX

$SWTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Lynch Daniel was granted 10,060 shares, increasing direct ownership by 12% to 93,004 units (SEC Form 4)

Director Lewis-Hall Freda C was granted 10,060 shares, increasing direct ownership by 69% to 24,727 units (SEC Form 4)

Director Hambleton Julie was granted 10,060 shares, increasing direct ownership by 246% to 14,155 units (SEC Form 4)

$SWTX
SEC Filings

SEC Form DEFA14A filed by SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc. filed SEC Form 8-K: Other Events

SEC Form DEFM14A filed by SpringWorks Therapeutics Inc.

HC Wainwright & Co. reiterated coverage on SpringWorks Therapeutics with a new price target

Chat with this insight

Recent Analyst Ratings for $SWTX

$SWTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Lynch Daniel was granted 10,060 shares, increasing direct ownership by 12% to 93,004 units (SEC Form 4)

Director Lewis-Hall Freda C was granted 10,060 shares, increasing direct ownership by 69% to 24,727 units (SEC Form 4)

Director Hambleton Julie was granted 10,060 shares, increasing direct ownership by 246% to 14,155 units (SEC Form 4)

$SWTX SEC Filings

SEC Form DEFA14A filed by SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc. filed SEC Form 8-K: Other Events

SEC Form DEFM14A filed by SpringWorks Therapeutics Inc.

Recent Analyst Ratings for
$SWTX

$SWTX
Insider Trading

$SWTX
SEC Filings